Transforming the Treatment Paradigm for Patients With MDS

Transforming the Treatment Paradigm for Patients With MDS

Friday, December 4, 2020
Webinar -- 3:00 PM PT


  • The Medical Need for Novel Therapies in MDS
  • Novel Therapeutic Approaches for the Treatment of MDS-Associated Anemia
  • Novel Therapeutic Approaches for the Treatment of MDS
  • Novel Therapeutic Approaches for the Treatment of Relapsed/Refractory MDS
  • Future Directions and Key Ongoing Clinical Trials in MDS


Program Director
Rami Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Guillermo Garcia Manero, MD

Professor, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jamile Shammo, MD, FASCP, FACP

Professor of Medicine and Pathology
Division of Hematology, Oncology, and Stem Cell Transplant
Director, MDS/MPN/Aplastic Anemia Program 
Rush University Medical Center
Chicago, Illinois

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to apply the latest practice-changing data in the individualized clinical management of patients with MDS.

Target Audience
This program is intended for hematologists and other clinicians involved in the management of patients with MDS.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate novel management options for managing MDS-related anemia
  • Evaluate emerging treatment options for the treatment of patients with lower, intermediate, and high risk MDS
  • Consider available treatment options and clinical trial enrollment for the management MDS
  • Plan novel therapeutic options for patients with relapsed/refractory disease
  • Identify patients with MDS who are candidates for ongoing clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.